Rationale Ethanol and nicotine are frequently co-abused. The biological basis for the high co-morbidity rate is not known. Alcohol-preferring (P) rats will self-administer EtOH or nicotine directly into the posterior ventral tegmental area (pVTA). Objective The current experiments examined whether subthreshold concentrations of EtOH and nicotine would support the development of self-administration behaviors if the drugs were combined. Methods Rats were implanted with a guide cannula aimed at the pVTA. Rats were randomly assigned to groups that selfadministered sub-threshold concentrations of EtOH (50 mg%) or nicotine (1 μM) or combinations of ethanol (25 or 50 mg%) and nicotine (0.5 or 1.0 μM). Alterations in gene expression downstream projections areas (nucleus accumbens shell, AcbSh) were assessed following a single, acute exposure to EtOH (50 mg%), nicotine (1 μM), or ethanol and nicotine (50 mg%+1 μM) directly into the pVTA.
Introduction
Ethanol and nicotine co-use/abuse is common. Individuals that are nicotine-dependent are ten times more likely to be diagnosed with alcoholism than non-smokers in their lifetime (DiFranza and Guerrera 1990) . The rate of smoking is high (between 80 and 97 %; John et al. 2003a,b) in alcoholics and has remained constant while the overall smoking rate has reduced (John et al. 2003a, b) . Co-abuse is associated with higher rates of drug craving, increased levels of drug consumption during relapse, reduction in clinical outcomes, and an increased rate of high levels of drug consumption (c.f., Gilbertson et al. 2011) . In non-addicted individuals, nicotine and alcohol co-use increases consumption of both drugs (AitDaoud et al. 2005) . The initiation of nicotine and ethanol couse typically begins in adolescence, which leads to greater detrimental adult outcomes than if a single drug is used during adolescence (Hingson et al. 2008) .
Despite the extensive clinical evidence that ethanol and nicotine co-abuse is pervasive, there has been insufficient basic research conducted to understand the biological basis of the co-abuse. The mesolimbic dopamine system has been hypothesized to be a critical neurocircuit for drug reward/ reinforcement. Independently, ethanol and nicotine are directly self-administered into the posterior ventral tegmental area (pVTA) at pharmacologically relevant concentrations (Rodd et al. 2004a; Ikemoto et al. 2006; Hauser et al. 2013) . The sensitivity of the pVTA to the reinforcing properties of nicotine and ethanol is influenced by genetic background. P rats self-infused nicotine in the range of 10-200 μM, while Wistar rats require a 50 μM concentration to support selfadministration (Hauser et al. 2013) . Ethanol was self-infused into the posterior VTA by P rats at concentrations as low as 75 mg%, while Wistar rats require an ethanol concentration of 125 mg% to support self-administration (Rodd et al. 2004a ). Systemically, P rats will establish intravenous nicotine selfadministration at a lower concentration than non-alcoholpreferring (NP) rats (Lê et al. 2006) . Lê et al. (2010 reported that unselected rats will simultaneously self-administer nicotine (iv) and EtOH (oral), but blood ethanol and/or nicotine levels were not reported.
Ethanol and nicotine interact within the mesolimbic dopamine system to alter self-administration, dopamine neurochemistry, and gene expression. Microinjection of nicotine acetylcholine receptor antagonists into the VTA decreases ethanol self-administration, while nicotine can increase ethanol self-administration and self-seeking (c.f., Hauser et al. 2012) . Systemic administration of nicotine and ethanol increases dopamine levels in the nucleus accumbens significantly more than following equivalent ethanol or nicotine exposure (Tizabi et al. 2002 (Tizabi et al. , 2007 Doyon et al. 2013 ). Coperfusion of ethanol and nicotine into the VTA results in stimulation of dopamine neurons that is not observed following equivalent exposure to ethanol or nicotine alone (Clark and Little 2004) . Most human genetic studies examining ethanol and nicotine have ignored co-abuse issues. In the VTA, chronic alcohol and nicotine use produced unique alterations in gene expression of glutamatergic transmission (Flatscher-Bader et al. 2008) . The current experiments determined whether a solution containing sub-threshold concentrations of ethanol and nicotine would be self-administered directly into the pVTA and whether alterations in gene expression in the nucleus accumbens shell (AcbSh) occurred following microinjection of a solution containing equivalent subthreshold concentrations of ethanol, nicotine, and ethanol and nicotine into the pVTA.
Methods
Animals P rats (71st and 72nd generations) weighing 250-320 g at time of surgery were used. Animals were doublehoused upon arrival and maintained on a 12-h reverse light-dark cycle (lights off at 0900 h). Food and water were freely available except in the test chamber. All research protocols were approved by the Institutional Animal Care and Use Committee and are in accordance with the guidelines of the Institutional Animal Care and Use Committee of the National Institute on Drug Abuse, NIH, and the Guide for the Care and Use of Laboratory Animals (National Research Council 1996) .
Data for subjects that did not complete all experimental test sessions were eliminated from the analyses. The number of animals indicated for each experiment represents 98 % of the total number that underwent surgery; 2 % of the animals were not included for analyses mainly due to the loss of the guide cannula before completion of all experimental sessions. The data for these animals were not used because their injection sites could not be verified.
Drug and vehicle
The artificial cerebrospinal fluid (aCSF) vehicle consisted of 120.0 mM NaCl, 4.8 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM Mg SO 4 , 25.0 mM NaHCO 3 , 2.5 mM CaCl 2 , and 10.0 mM D-glucose. Nicotine tartrate (Sigma-Aldrich, St. Louis, MO USA) and ethyl alcohol (190 proof; McCormick Distilling Co., Weston, MO) were dissolved in the aCSF solution. When necessary, 0.1 M HCl or 0.1 M NaOH was added to the solutions to adjust pH levels to 7.4±0.1.
Apparatus
The test chambers and electrolytic microinfusion transducer (EMIT) system have been previously described (Rodd-Henricks et al. 2003; Rodd et al. 2004a, b) and were used to control microinfusions of nicotine, ethanol, ethanol and nicotine, or vehicle.
Animal preparation Animal surgery was conducted as outlined in previous manuscripts (Rodd-Henricks et al. 2003; Rodd et al. 2004a, b) . Animals were handled for at least 5 min daily following the fourth recovery day. Subjects were not acclimated to the test chamber prior to the commencement of data collection, nor were they trained on any other operant paradigm.
General test condition For testing, subjects were brought to the testing room, the stylet was removed, and the injection cannula screwed into place. Rats were placed individually in the test chamber. To avoid trapping air at the tip of the injection cannula, the infusion current was delivered for 5 s during insertion of the injector that resulted in one noncontingent administration of nicotine or aCSF at the beginning of the session. Injection cannula extended 1.0 mm beyond the tip of the guide. The test chamber was equipped with two levers. Depression of the "active lever" (FR1 schedule of reinforcement) caused the delivery of a 100-nl bolus of infusate over a 5-s period followed by a 5-s timeout period. During both the 5-s infusion period and 5-s timeout period, responses on the active lever did not produce further infusions. The assignment of active and inactive lever with respect to the left or right position was counterbalanced among subjects. However, the active and inactive levers remained the same for each rat throughout the experiment. No shaping technique was used to facilitate the acquisition of lever responses. The number of infusions and responses on the active lever was recorded. Responses on the "inactive lever" were recorded but did not result in infusions. The duration of each test session was 4 h and sessions occurred every other day.
Experiment 1-ethanol + nicotine co-administration in female P rats in the posterior VTA Female rats were randomly assigned to one of seven groups (n=58; 8-9/group). Rats were allowed to self-administer aCSF, ethanol alone (50 mg%), nicotine alone (1 μM), or combinations of ethanol and nicotine (12.5 mg% ethanol+1 μM nicotine, 25 mg% ethanol+1 μM nicotine, 50 mg% ethanol+1 μM nicotine, and 50 mg% ethanol+0.5 μM nicotine). The original infusate solution was available for self-administration during the first four sessions (acquisition). During the fifth and sixth sessions (extinction), all animals received infusions of aCSF. On the seventh session, rats were allowed to respond for their originally assigned infusate.
Experiment 2-ethanol + nicotine co-administration in male P rats in the posterior VTA Male rats were randomly assigned to one of four groups (n=27; 6-8/group). Rats were allowed to self-administer aCSF, ethanol alone (50 mg%), nicotine alone (1 μM), or ethanol and nicotine (50 mg% ethanol+1 μM nicotine). The seven sessions were conducted as described for experiment 1.
Experiment 3-alteration in gene expression in the AcbSh produced by co-administration of ethanol + nicotine in the posterior VTA To standardize the amount of ethanol and/or nicotine received between groups, a passive microinjection protocol was employed using the same EMIT units described in experiments 1 and 2. Female P rats had cannulas aimed at the pVTA to receive the passive microinjections in a pattern that mirrored intracranial self-administration (ICSA) self-administration. Microinjections occurred over a 10-min period. A pattern of a 5-s pulse microinjection followed by a 15-s timeout period was used to produce 30 total microinjections (a total obtained by some self-administering rats). Rats were randomly assigned to one of four groups (n=25; 5-7/group): aCSF, ethanol alone (50 mg%), nicotine alone (1 μM), or ethanol and nicotine (50 mg% ethanol+1 μM nicotine). Previous research indicated that microinjection of the low concentration of ethanol (50 mg%) into the pVTA would not induce a significant alteration in dopamine levels in the Acb (Ding et al. 2009 ).
Tissue collection Three hours after the passive microinjection (aCSF, nicotine, ethanol, or combination of nicotine and EtOH), rats were euthanized and brains were removed and frozen in isopentane chilled with dry ice (approximately −50°C). Brains were then stored at −80°C until processed.
Tissue preparation and micropunch for RT-PCR All equipment and working surfaces were kept RNase free during dissection of the regions of interest. Frozen brains were sliced at 300 μm (coronal), using a Leica cryostat, and slices were placed onto microscope slides. Locations of injectors were verified in the slices using a Leica dissecting microscope set to ×4 magnification. The shell of nucleus accumbens, ipsilateral to the injection, was dissected out of seven adjacent 3,000-μm coronal brain slices (from approximately 2.76 to 0.96 mm from bregma; Paxinos and Watson 2005) using a 1.0-mm Harris Micro-punch (Electron Microscopy Sciences, Hatfeild, PA) after first removing the accumbens core. The AcbSh tissue was immediately placed into 75 μl of SurePrep TM TrueTotal TM RNA purification buffer (Fisher Scientific), and samples were vortexed and frozen on dry ice and kept at −80°C overnight.
RNA was isolated using SurePrep TM TrueTotal TM RNA Purification Kit (Fisher Scientific). Total RNA was determined using Nanodrop 1000. Extracted RNA was then reverse transcribed using the GeneAmp Gold RNA PCR kit (Applied Biosystems) at the following reaction conditions: 2.5 μM Oligo-dT primer, 2.5 mM magnesium, 250 mM of each deoxynucleotide triphosphate, 0.5 U/ml of RNase inhibitor, and final concentration of 0.75 U/μl of MuLV reverse transcriptase. The reverse transcription conditions were 10 min at room temperature, 15 min at 42°C, 10 min at 68°C, and 5 min at 95°C and produced approximately 25 μl of product.
Taqman low-density arrays (TLDA) Each microfluidic card of the custom-designed gamma-aminobutyric acid (GABA)/Glutamate TaqMan low-density array has eight separate loading ports (two ports per sample), each with 48 separate wells per loading port, making 96 wells per sample. Each 2-μl well contains specific, user-defined primers and probes, capable of detecting a single gene. In this study, the mRNA levels of 89 genes associated with amino acid neurotransmitters as well as the neuronal plasticity markers brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) were included.
A cDNA sample (100 μl) isolated from the AcbSh from each rat was added to an equal volume of TaqMan® universal PCR master mix (Applied Biosystems). After gentle mixing and centrifugation, the mixture was transferred to a loading port on a TLDA card. The array was centrifuged twice for 1 min, each at 1,200 rpm, to distribute the samples from the loading port to each well. The card was then sealed and PCR amplification performed using an Applied Biosystems Prism 7900HT sequence detection system (equipped with a TaqMan® low-density array upgrade). Thermal cycler conditions were as follows: 2 min at 50°C, 10 min at 94.5°C, 30 s at 97°C, and 1 min at 59.7°C for 40 cycles. A common threshold was set for all genes using RQ manager software (ABI). The Ct values obtained from the RQ manager (ABI) were then imported into RealTime StatMiner v4.5 (Integromics) for further analyses.
Reference gene selection The TLDAs included 18S, glyceraldehyde 3-phosphate dehydrogenase (Gapdh), hypoxanthine phosphoribosyltransferase 1 (Hprt1), ribosomal protein, large, P2 (Rplp2), and ubiquitin C (Ubc) as reference genes based on their proven role as housekeeping genes and their uniform expression in preliminary TLDA rat endogenous control assays from rat AcbSh (data not shown). The geNORM procedure, also known as the pairwise approach, included in the RealTime StatMiner (Integromics) software was utilized to determine the stability of the selected reference genes, as described previously (Vandesompele et al. 2002) . Using this approach, the following genes were selected for normalization of gene expression levels: Gapdh, Hprt1, and Ubc.
Data analysis Expression of each gene relative to the control (aCSF) treatment group was calculated using the delta Ct method. These values were then converted to log 10 (log 10 (ΔΔCt)) for statistical analyses and graphing.
Results
Experiment 1-ethanol + nicotine co-administration in female P rats in the posterior VTA Two analyses were performed on the data set. The first analysis examined the average number of infusions self-administered during the first four sessions. An analysis of variance (ANOVA) indicated that there was a significant effect of drug condition (F 7, 50 =8.6; p<0.001; Fig. 1 ). Post hoc comparisons (Tukey's) indicated that female P rats self-administering 25 mg% ethanol+1 μM nicotine (38.2±4.5 infusions/session) or 50 mg% ethanol+ 1 μM nicotine (44.1±6.1 infusions/session) administered significantly more infusions than all other groups (range from 8.7 ±3.5 to 15.6±6.8).
The second analysis examined the number of lever responses (active and inactive) as a function of drug condition across all sessions (mixed factor ANOVA with between subject factor of drug condition and within subject factors of lever and sessions). The analysis revealed a significant drug condition × lever × session interaction (F 42, 300 =2.2; p<0.001). The interaction term was decomposed by examining lever responses across sessions within each drug condition. In female P rats self-administering aCSF, 1 μM nicotine, 50 mg% ethanol, or 50 mg% ethanol+0.5 μM nicotine, there were no significant terms (p values>0.33). In female P rats selfadministering 25 mg% ethanol+1 μM nicotine, or 50 mg% ethanol+1 μM nicotine (Figs. 2 and 3 ), there were significant lever × session interactions (p values<0.001). For these groups, there was lever discrimination during sessions 1-4 and 7 (p values<0.001). In addition, during aCSF substitution (extinction, sessions 5 and 6), there were significant reductions in the number of active lever responses (compared to session 4) and a loss of discrimination between active and inactive levers (p values<0.001). During reinstatement (session 7), the number of active lever responses returned to levels observed prior to extinction and there was again lever discrimination. In female P rats self-administering 50 mg% (Figs. 2 and 3) , there was also an effect of session (p values<0.021). The effect of session in both groups was based upon an increase in responding during session 7, which was significantly higher than that observed during sessions 4 and 6 (t test; p values< 0.007).
Experiment 2-ethanol + nicotine co-administration in male P rats in the posterior VTA The statistical analyses were conducted identically for the male data as those performed on the female data. Similarly, there was a significant effect of drug condition (F 3, 22 =14.9; p<0.001; Fig. 1 ) on the average number of infusions self-administered during sessions 1-4. Post hoc comparisons (Tukey's) indicated that male P rats self-administering 50 mg% ethanol+1 μM nicotine (43.3± 6.8 infusions/session) administered significantly more infusions than all other groups (range from 9.4±3.8 to 12.3±5.5). A significant drug condition × lever × session interaction (F 18, 132 =2.4; p<0.001) was revealed in the analysis examining active and inactive lever responses. In male P rats selfadministering 50 mg% ethanol+1 μM nicotine, the number of responses was significantly higher than all other groups during sessions 1-4 (Fig. 4) , and these rats discriminated between the active and inactive levers (p values<0.003). Similar to the female rats, male P rats self-administering 50 mg% ethanol+1 μM nicotine displayed extinction during aCSF substitution and reinstated during session 7 (p values< 0.002). In male P rats self-administering 1 μM nicotine, there was also an increase in responding during session 7 compared to sessions 4 and 6 (p values<0.001).
Experiment 3-alteration in gene expression in the AcbSh produced by co-administration of ethanol + nicotine in the posterior VTA Overall, the expression of nine genes was altered in the AcbSh following microinjections of drugs into the pVTA (Figs. 5 and 6 ). For interpretation purposes, we used a strict statistical approach in defining additive and synergistic effects. Additive effects were defined as statistical findings that would indicate the aCSF was significantly different from the EtOH alone or Nic alone group(s), while the EtOH + nicotine group was significantly different from the EtOH alone or Nic alone groups. Synergistic effects were defined as statistical findings indicating that only the EtOH + nicotine group was significantly different from the aCSF controls. In addition, the y-axis scales in Figs. 5 and 6 are in log 10 . Therefore, there is a visual bias to "observe" additive effects instead of synergistic effects in the figures (detailed for BDNF).
Neurotrophic factors Overall, the data indicated that acute microinjections of 50 mg% ethanol+1 μM nicotine into the pVTA resulted in unique alterations in gene expression in the AcbSh that were not observed following equivalent exposure Fig. 2 Depicts the mean (±SEM) active and inactive lever presses for female P rats given 50 mg% ethanol (EtOH; top panel), 50 mg% EtOH+ 1 μM nicotine (Nic; middle panel), or 1 μM Nic (bottom panel) directly into the posterior VTA. Asterisk indicates significantly greater responding on the active lever than responding for aCSF and significantly more responding on the active than inactive lever. Responses on the active and inactive levers for aCSF for all seven sessions are not shown but are similar to responses on the active and inactive lever for 50 mg% EtOH (top panel) Fig. 3 Mean (±SEM) active and inactive lever presses for female P rats given ethanol + nicotine (50 mg% EtOH+0.5 μM Nic or 25 mg% EtOH+1 μM Nic) to self-infuse into the posterior VTA. Asterisk indicates significantly greater responding on the active lever than responding for aCSF and significantly more responding on the active than inactive lever to ethanol or nicotine (Fig. 5) . This phenomenon was clearly indicated by the analyses performed on the neurotrophic factors BDNF and GDNF. Compared to aCSF injections (ANOVA F 3, 15 =4.428, p=0.026; F 3, 15 =4.418, p=0.030, respectively: Fig. 5 ), the 50-mg% ethanol+1 μM nicotine group had a 50-fold increase (SEM±1.3) in Bdnf expression compared to controls (SNK p=0.003) and significantly lower expression of Gdnf compared to controls (−2.4 fold) and EtOH only-treated rats (p=0.005, 0.036, respectively). Bdnf levels in some members of the aCSF, 50 mg% ethanol (5.9± 2.8 fold change compared to aCSF), and 1 μM nicotine (8.9± 4.1 fold change compared to aCSF) groups were near detection limits. For Gdnf, the 50-mg% ethanol+1 μM nicotine group was the only group with expression values near detection limits, while Gdnf expression in all other groups was readily detected.
GABA receptor and receptor subunits The only gene encoding GABA receptors or receptor subunits that was significantly altered by drug injection into the pVTA was the GABA B2 receptor (Gabbr2, ANOVA F 3, 15 =4.46, p=0.025; Fig. 6 ). Expression of Gabbr2 was significantly increased (1.6-fold versus control) compared to control, EtOH only, and Nic only groups (p=0.006, 0.018, and 0.018, respectively). Expression of genes encoding the subunits of GABA A receptors in the AcbSh were not significantly altered by the acute exposure to either drug or the combination of drugs, although a trend was observed for GABA A receptor alpha 3 (Gabra3) and alpha 4 (Gabra4) subunits (ANOVA F 3, 15 = 3.35, p=0.056 and F 3, 15 =3.00, p=0.073), with the combined treatment trending toward an increased expression of Gabra3 and reduced expression of Gabra4 compared to controls. The expression of the three genes encoding the GABA rho receptor did not reach detection limits in our assay (data not shown).
GABA-related genes In addition to GABA receptors and subunits, the effects of pVTA microinjections of ethanol, nicotine, or ethanol + nicotine on expression of GABA-related genes in the AcbSh were also determined. Expression of both of the GABA-synthesizing enzymes genes and glutamic acid decarboxylase 1 and 2 (Gad1 and Gad2) was significantly reduced (Gad1 −1.4; Gad2 −1.4, ANOVA F 3, 15 =3.56, p=0.048 and F 3, 15 =5.24, p=0.015; Fig. 6 ). Specifically, expression of Gad1 and Gad2 was significantly reduced compared to control group (p=0.035, 0.008) and EtOH group (p=0.014, 0.003). No significant changes in gene expression were observed for GABA transporters or GABA A -binding proteins (data not shown).
Glutamate receptor and receptor subunits The only gene encoding glutamate receptors or receptor subunits that was significantly altered by drug injection into the pVTA was metabotropic glutamate receptor 2 (Grm2, ANOVA F 3, 15 = Fig. 4 Mean (±SEM) active and inactive lever presses for male P rats given 50 mg% ethanol (EtOH; top panel), 50 mg% EtOH+1 μM nicotine (Nic; middle panel), or 1 μM Nic (bottom panel) to self-infuse into the posterior VTA. Asterisk indicates significantly greater responding on the active lever than responding for aCSF and significantly more responding on the active than inactive lever. Responses on the active and inactive levers for aCSF for all seven sessions are not shown but are similar to responses on the active and inactive lever for 50 mg% EtOH (top panel) Fig. 5 Neurotrophic genes that significantly changed in the Acbsh following administration of 50 mg% ethanol+1 μM nicotine into the pVTA (BDNF, GDNF). Asterisk indicates significantly higher expression in the 50-mg% ethanol+1 μM nicotine group compared to all other groups 4.18, p=0.031; Fig. 6 ). Expression of Grm2 was significantly increased (3.2 versus control) in the ethanol + nicotine group compared to control, ethanol, and nicotine groups (p=0.04, 0.016, and 0.028, respectively). In addition to Grm2, there was a trend toward reduction of the metabotropic glutamate receptor Grm4 (ANOVA F 3, 15 =2.98, p=0.074) in the combined group compared to controls. Expression of genes encoding the subunits of ionotropic glutamate receptors (NMDA, AMPA and Delta, and Kainate; data not shown) in the AcbSh was not significantly altered by the acute pVTA exposure to drug(s).
Glutamate-related genes In addition to glutamate receptors and subunits, the effects of pVTA injection of ethanol, nicotine, or ethanol + nicotine on expression of glutamate-related genes in the AcbSh were also determined. Expression of two of the vesicular glutamate transporters, 1 and 3 (vesicular glutamate transporter (Vglut)1 and Vglut3), was significantly altered by pVTA microinjections (ANOVA F 3, 15 =3.56, p= 0.048 and F 3, 15 =5.24, p=0.015; Fig. 6 ), and vesicular glutamate transporter 2 (Vglut2) expression had a strong trend (ANOVA F 3, 15 =3.48, p = 0.0502). In rats administered 50 mg% ethanol+1 μM nicotine into the pVTA, expression of Vglut1 was increased 10.3 relative to aCSF controls and was significantly greater than aCSF controls and the nicotine group (p=0.006, 0.045, respectively). Expression of Vglut3 was significantly reduced (−1.9 versus control) by combined ethanol + nicotine microinjections into the pVTA compared to all other groups (p=0.003, 0.004, and 0.046). No significant changes in gene expression were observed for plasma membrane glutamate transporter genes, AMPA receptor trafficking genes, or glutamate receptor binding proteins (data not shown).
Glycine receptor There was only one significant alteration in the glycine receptor system, the glycine receptor alpha subunit 4 (gl4a). Statistically, there was a significant reduction in the gl4a subunit in the AcbSh in nicotine administered rats compared to the aCSF and EtOH groups (p values<0.03), and ethanol and nicotine co-microinjections further enhanced this reduction (significantly different from all other groups; pvalues<0.02).
Discussion
The current results support the hypothesis that the pVTA is one site where ethanol and nicotine interact in the brain to initiate and promote their co-use, as a result of their synergistic interactions at low doses. The reinforcing effects of the mixture of ethanol + nicotine are supported by the findings that clear lever discrimination occurred during the first four sessions, lever discrimination was lost and responses on the active lever decreased when aCSF alone was given in sessions 5 and 6, and responding on the active lever increased when the mixture was returned (Figs. 2, 3, and 4) . Furthermore, the acute exposure of the pVTA to the mixture of low concentrations of ethanol and nicotine produced significant changes in the expression of genes that could alter glutamate and GABA Fig. 6 GABAergic, glutamatergic, and glycine-related genes that significantly changed in the Acbsh following administration of 50 mg% ethanol+1 μM nicotine into the pVTA. Plus symbols indicated significantly higher expression in the 50-mg% ethanol+1 μM nicotine compared to all other groups (post hoc; SNK). Asterisk indicates significantly lower expression in the 50-mg% ethanol+1 μM nicotine group compared to water and 50 mg% ethanol groups. Number symbol indicates significantly higher expression in the 50-mg% ethanol+1 μM nicotine compared to water. Circumflex accent symbol indicates significantly lower expression in the 1 μM nicotine compared to water receptor synaptic function in the AcbSh, suggesting that this feed forward pathway for processing the rewarding effects of ethanol and nicotine may have been activated.
The synergistic interaction of ethanol and nicotine within the pVTA may be a result of their acting at different receptor sites, and/or at the same receptor, where the presence of nicotine (or ethanol) alters the functional response of the receptor to ethanol (or nicotine). Nicotinic and 5-HT 3 receptors have been found to be co-localized on nerve terminals (Nayak et al. 2000) . Therefore, it is possible that these two receptors may be co-localized on VTA dopamine neurons; local perfusion of nicotine (Rahman et al. 2004 ) or a 5-HT 3 agonist ) stimulated somatodendritic dopamine release in the VTA.
Ethanol and nicotine act directly at the 5-HT 3 receptor (nicotine binds at a lower affinity to the 5-HT 3 receptor than any cholinergic nicotinic receptor; Jackson and Yakel 1995) . The reinforcing properties of both ethanol and nicotine are mediated by the 5-HT 3 receptor (Rodd-Henricks et al. 2003; Hauser et al. 2013 ). Therefore, it is possible that the synergistic actions of ethanol and nicotine are mediated in part by the activation of 5-HT 3 receptors.
The synergistic interaction of ethanol and nicotine in the pVTA to produce reinforcement is most likely predicated upon the ability of the mixture to stimulate dopamine neurons that are not observed following exposure to equivalent concentrations of ethanol or nicotine alone (Clark and Little 2004) . Evidence supports the idea that the reinforcing effects of ethanol or nicotine within the posterior VTA are mediated by activating local dopamine neurons (Pidoplichko et al. 2004; Rodd et al. 2004b) . Neither 50 mg% ethanol nor 1 μM nicotine is self-administered into the pVTA, suggesting this concentration of each drug is not sufficient to activate VTA dopamine neurons. On the other hand, the mixture of these inactive concentrations of ethanol and nicotine is readily self-infused into the pVTA, suggesting activation of local DA neurons is occurring.
Smokers can readily obtain blood nicotine concentrations that exceed the levels that were used in the current experiment (Benowitz 1997) . The ethanol concentration used is below the level of intoxication in humans. P rats will orally self-administer solutions of ethanol and nicotine (15 % and 0.14 mg/ml) daily at rates that produce blood ethanol and nicotine concentrations that approach those used in the current experiments (>80 mg% and 27 ng/ml, respectively; Hauser et al. 2012) . The actual concentration of nicotine in the brain following microinjection is probably lower than that emitted in the current ICSA experiments, and may approach the levels observed following oral EtOH + nicotine self-administration in P rats (167 nM). Therefore, biologically relevant levels of ethanol and nicotine can act synergistically within the pVTA to produce reinforcement. Ikemoto et al. (2006) reported that nicotine was selfadministered directly into the posterior VTA at concentrations starting at 25 mM in Wistar rats. These levels are approximately 4,500-fold higher than clinically relevant levels of nicotine and are well beyond the neurotoxic levels of nicotine (Toledano and Toledano-Diaz 2010; Ferrea and Winterer 2009) . Similarly, the actual levels of nicotine established in the pVTA are probably lower than 25 mM but are likely still toxic. The toxicity of the nicotine levels employed could partial explain the failure to replicate self-administration of 2 5 m M n i c o t i n e i n t o t h e p V TA i n n a ï v e a n d nicotine-"sensitized" rats (Farquhar et al. 2012) . In mice (Exley et al. 2011) , nicotine is self-administered directly into the pVTA at concentrations comparable to those used in the current experiments and by Hauser et al. (2013) .
The results also indicate that a single, acute exposure to ethanol and nicotine together in the pVTA produces alterations in gene expression in the AcbSh that are not observed following equivalent microinjections of only ethanol or nicotine (Figs. 5 and 6). Alterations in gene expression in other brain regions produced by microinjections of EtOH + nicotine into the pVTA are likely to occur but were not assessed in the current experiments. Increases in BDNF levels are associated with the promotion of synaptic plasticity that underlies the development of appetitive and aversive emotional learning (Choi et al. 2012) . BDNF levels are increased in the VTA and Acb following chronic drug exposure (Bolanos and Nestler 2004) . BDNF infusions into the VTA create a neurological state that mimics opiate addiction (Vargas-Perez et al. 2009 ). Increases in BDNF levels in the Acb or amygdala are associated with chronic ethanol (Moonat et al. 2011) , cocaine (Li et al. 2013) , and nicotine (Perna and Brown 2013) use and the promotion of drug-seeking (Li et al. 2013) . In general, Bdnf expression was low in the Acb for the aCSF, ethanol, and nicotine groups, but transcription was dramatically increased (50-fold) by coadministration of ethanol and nicotine in the pVTA. In contrast, GDNF levels in the aCSF, ethanol, and nicotine groups were readily detected, but the expression level in the ethanol and nicotine group decreased to detection level thresholds.
GDNF levels in the mesolimbic dopamine system are positively associated with a reduction in drug use/drug-seeking. GDNF has neuroprotective properties within the mesolimbic dopamine system through regulation of neuronal excitability and transmitter release (Beck et al. 1995; Wang et al. 2001) . Intra-VTA infusions of GDNF reduced cocaineinduced conditioned place preference, reduced alterations in the VTA produced by chronic morphine administrations, and can reduce a number of ethanol self-administration behaviors (Messer et al. 2000; He et al. 2005; Carnicella et al. 2008 . The general inhibitory effect of GDNF on drug use/ drug-seeking has lead to the promotion of GDNF as a potential pharmacotherapy for the treatment of drug addiction ).
In post-mortem brains of alcoholics (no exclusion for nicotine use) and cocaine users, expression levels of GABA-B receptors were altered, and the expression of GAD1 and GAD2 was reduced (Enoch et al. 2011) . The observation that similar effects on GABA-B and GAD expression levels were detected following exposure to multiple drugs of abuse suggests the possibility that these components of the GABA system are potential pharmacological targets for the treatment of drug addiction (Enoch et al. 2011) . Alterations in the expression levels of GABA-related genes in the AcbSh following pulse microinjections of ethanol, nicotine, or ethanol + nicotine were limited (Fig. 6) . Yet, the current findings also indicate a significant reduction in Gad1 and Gad2 expression levels in the AcbSh following microinjections of only ethanol and nicotine into the pVTA.
The alterations in the glutamatergic corticostriatal pathway are thought to produce neuroplasticity that is the basis of addiction (glutamate homeostasis hypothesis; Kalivas 2009). Glutamate homeostasis, the regulation of glutamate levels within the synaptic cleft, is determined by glutamatergic release and glial and synaptic uptake (Diamond and Jahr 1997) . Extracellular levels of glutamate are primarily regulated by the cystine-glutamate transport (C-GT) and the vesicular glutamate transporters (VGlut1-3; c.f. Kalivas 2009) . Activation of the C-GT in the Acb enhances mGlu2 receptors' reduction of synaptic glutamate release (Moran et al. 2005) . VGlut1 levels are reduced in the Acb core following nicotine or cocaine selfadministration (Knackstedt et al. 2009 (Knackstedt et al. , 2010 . The current data indicate only the ethanol + nicotine microinjections into the pVTA increased the expression of mGlu2 and VGlut1 and a decrease in VGlut3 (Fig. 6 ). VGlut3 is located on cholinergic neurons, not GABA medium spiny neurons (MSN) in the AcbSh, and is co-localized with neurokinin 1 receptors (Commons and Serock 2009) . Therefore, the data suggest that following microinjections of ethanol and nicotine into the pVTA, there was an increase in activity in MSN and a reduction in the inhibitory cholinergic system within the AcbSh.
The current experiments did not exhaustively examine the interaction between ethanol and nicotine on reinforcement within the pVTA (e.g., determining if adding a sub-threshold concentration of nicotine would increase established ethanol self-administration); therefore, other ethanol-nicotine interactions within the pVTA, and other brain regions, are possible. In addition, the object of the current experiment was not designed to determine alterations in gene expression in the AcbSh produced by microinjections of reinforcing concentrations of ethanol or nicotine (determination of unique effects of ethanol and nicotine).
In humans, nicotine usage can increase alcohol consumption, and alcohol consumption can increase nicotine usage (c.f. Ait-Daoud et al. 2005) . Self-reports from alcoholics and nicotine-dependent individuals indicated that there is a positive correlation between the number of cigarettes smoked and amount of alcohol consumed (True et al. 1999) . The dual propagation of ethanol and nicotine use in humans may be based upon the ability of these drugs to act synergistically, or in other promoting manners, to decrease reward thresholds, or to enhance reward experience. The current experiments indicate that the pVTA is a neuroanatomical site where ethanol and nicotine can synergistically act to produce reinforcement and that alterations in gene expression in the mesolimbic dopamine system (AcbSh) produced by ethanol and nicotine exposure may enhance future drug use.
